The Appili management team is advised by a Board of Directors who brings deep expertise in infectious disease, drug development, innovative financing models, and biopharmaceutical senior management roles.
Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s Chairman and Chief Executive Officer. By forging unique relationships with international healthcare-specialized investors, Brian raises capital for Canadian healthcare companies while helping investors realize returns.
Brian is a member of the Life Sciences Advisory Board at the National Research Council of Canada and also serves on the Board of Directors at BIOTECanada, the Baycrest Foundation. Brian is also the Chairman of the Board of Triumvira Immunologics, Appili Therapeutics and Grey Wolf Animal Health, and on the Board of Directors of Qing Bile Therapeutics.
Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics.
John Holyoake, DPhil
John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. At Bloom Burton, John’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. John’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a particular focus on preclinical-stage biotech. John has previous industry experience with the clinical stage oncology company TenX BioPharma and the life science consulting group SHI Link, as well as with several early-stage life science companies. He currently serves on the Board of directors of Triumvira Immunologics and Appili Therapeutics. John holds a Master’s in Biochemistry and Doctorate from the University of Oxford, and made the transition across the Atlantic for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.
Dr. Lidija Marusic
Dr. Lidija Marusic is an investment manager at Innovacorp, a venture capital fund investing in seed and early-stage technology companies. With over 15 years of experience in life science technology commercialization, Lidija manages all aspects of the investment due diligence, approval and closing cycle, and works hands-on with Innovacorp’s portfolio companies. Prior to joining Innovacorp, Lidija worked at MDS Capital Corp. (now Lumira Capital) and its seed fund MedInnova Partners Inc., focusing on commercializing biomedical discoveries. Lidija holds a Doctor of Medicine degree from the University of Zagreb, a PhD in molecular genetics from the International School for Advanced Studies (SISSA/ISAS) and an MBA from McMaster University. She served on the International Peer Review Panel for the Canadian Networks of Centres of Excellence (NCE) and on the Proof of Principle Peer Review Committee of the Canadian Institutes for Health Research (CIHR). Lidija is a member of the board of directors for DeCell Technologies Inc., DGI Clinical Inc. and DeNovaMed Inc., and a board observer at ABK Biomedical Inc. and Densitas Inc.
Mr. Nicolle has 20 years of experience leading companies and growing shareholder value. He is currently president of Cape Bear Advisors where he consults and holds numerous board positions, including vice chair of the start-up accelerator Propel ICT. Mr. Nicolle is the former CEO of leading healthcare technology company, STI Technologies, where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of 500 per cent. Before STI Technologies Mr. Nicolle spent 10 years leading venture-backed technology companies, including: CEO of Tatara Systems, CEO of Sigma Systems, COO at March Networks, and President of Nortel’s Service Provider eBusiness Solutions Group. He is a graduate of Western University with an honours degree in computer science.
Mr. Mortimer has over 20 years of experience in the biotechnology sector. He is currently Chief Financial Officer and Chief Operating Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a company developing medicines to treat neurological disorders. Prior to joining Xenon in 2013, Mr. Mortimer spent six years at Tekmira Pharmaceuticals Corporation, now Arbutus Biopharma Corporation (NASDAQ: ABUS), as Executive Vice President and Chief Financial Officer. He led both Xenon’s and Tekmira’s listings on the NASDAQ, in 2014 and 2010 respectively. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer of Inex Pharmaceuticals Corporation. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia, and is a Chartered Professional Accountant, Certified Management Accountant.
Kevin Sullivan, MBA
Appili CEO Kevin Sullivan has more than 21 years of experience working with early-stage biotechnology companies and has raised over $50 million in private equity and non-dilutive government funding in the space. Before joining Appili, he was CEO at DeNovaMed, Inc., a company focused on Gram-positive and Gram-negative antibiotics, and COO at Viron Therapeutics, which is develops novel immunotherapies. He is also a former diver in the Canadian Navy, and retains a familiarity with and commitment to resolving medical challenges faced by the military.